指南与共识血栓与止血

妊娠期COVID-19凝血病:批判性综述、初步推荐及ISTH登记处——来自ISTH女性健康科学标准化委员会的通讯

COVID-19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry-Communication from the ISTH SSC for Women's Health.
指南 / 共识 · J Thromb Haemost · 2020-10-14

由国际血栓与止血学会女性健康科学标准化委员会组织专家协作,经结构化文献检索与证据质量评估,针对妊娠期COVID-19凝血病制定初步推荐,并建立国际登记处收集数据以支持管理。

要点

  • 妊娠期COVID-19凝血病缺乏随机临床试验数据,推荐基于非妊娠和妊娠人群的中至高质量偏倚风险研究共识。
  • 制定了针对COVID-19合并凝血病或血栓并发症孕妇的初步推荐以辅助临床管理。
  • 建立了国际登记处,用于收集数据以支持妊娠期COVID-19及相关凝血病的管理。

核心结论

  • 制定了妊娠期COVID-19凝血病的初步推荐,并建立国际登记处以收集数据支持管理。

研究设计与样本

  • 由国际血栓与止血学会女性健康科学标准化委员会组织专家协作,经结构化文献检索、证据质量评估及委员会评审批准。
  • 基于非妊娠和妊娠人群已发表研究,采用Newcastle-Ottawa量表评估偏倚风险为中至高度,并承认缺乏随机临床试验数据。

主要发现

  • 强调了妊娠期特有的止血问题。
  • 一项纳入2567名孕妇的大型系统综述和Meta分析显示,7%需要重症监护,孕产妇死亡率约1%,围产期死亡率低于1%。

关键数值与推荐

  • 初步推荐用于协助管理COVID-19合并凝血病或血栓并发症的孕妇。
  • 推荐基于非妊娠和妊娠人群已发表研究,偏倚风险中至高度,无随机临床试验数据。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 缺乏随机临床试验数据用于管理感染SARS-CoV-2的孕妇。
  • 基于的已发表研究偏倚风险为中至高度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel coronavirus (SARS-CoV-2), which causes COVID-19, has thus far affected more than 15 million individuals, resulting in more than 600 000 deaths worldwide, and the number continues to rise. In a large systematic review and meta-analysis of the literature including 2567 pregnant women, 7% required intensive care admission, with a maternal mortality ~1% and perinatal mortality below 1%. There has been a rapid increase in publications on COVID-19-associated coagulopathy, including disseminated intravascular coagulopathy and venous thromboembolism, in the non-pregnant population, but very few reports of COVID-19 coagulopathy during pregnancy; leaving us with no guidance for care of this specific population. METHODS: This is a collaborative effort conducted by a group of experts that was reviewed, critiqued, and approved by the International Society on Thrombosis and Haemostasis Subcommittee for Women's Health Issues in Thrombosis and Hemostasis. A structured literature search was conducted, and the quality of current and emerging evidence was evaluated. Based on the published studies in the non-pregnant and pregnant population with a moderate to high risk of bias as assessed by Newcastle-Ottawa scale and acknowledging the absence of data from randomized clinical trials for management of pregnant women infected with SARS-CoV-2, a consensus in support of a guidance document for COVID-19 coagulopathy in pregnancy was identified. RESULTS AND CONCLUSIONS: Specific hemostatic issues during pregnancy were highlighted, and preliminary recommendations to assist in the care of COVID-19-affected pregnant women with coagulopathy or thrombotic complications were developed. An international registry to gather data to support the management of COVID-19 and associated coagulopathy in pregnancy was established.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kadir RA, Kobayashi T, Iba T, et al. COVID-19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry-Communication from the ISTH SSC for Women's Health. J Thromb Haemost. 2020. PMID: 32846051. doi:10.1111/jth.15072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。